Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
Ascendis Pharma A stock last closed at $194.30, up 0.78% from the previous day, and has increased 39.39% in one year. It has overperformed other stocks in the Biotechnology industry by 1 percentage points. Ascendis Pharma A stock is currently +74.9% from its 52-week low of $111.09, and -2.85% from its 52-week high of $199.99.
There are currently 60.69M ASND shares outstanding. The market cap of ASND is $11.79B. In the past 24 hours, 308,000 ASND shares were traded.
You need an online brokerage account to access the NASDAQ market and buy ASND shares.
We believe that eToro is the best place to buy stocks. eToro gives you:
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've picked the right brokerage, you'll need to fill out some personal information so you can buy ASND stock today.
Now that you've filled out your info on the best stock broker app, your next step is to transfer the money for your investment:
Check out this video walkthrough for more details depositing funds into your new investment account.
After you have chosen the best place to buy Ascendis Pharma A stock, it's very important to evaluate their stock prior to investing, so you actually comprehend the risk and opportunity.
WallStreetZen was designed to help average investors perform better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on ASND's stock page.
You can use many financial metrics, analyses, models, and charts to gauge ASND's fair value.
You can access more valuation analysis on ASND's stock here.
Out of 13 Equities analysts who track ASND, the consensus analyst rating on ASND is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Li Watsek, a bottom 11% analyst from Cantor Fitzgerald maintains ASND with a strong buy rating and raises their ASND price target from $200.00 to $203.00, on Aug 8, 2025.
Derek Archila, a top 3% analyst from Wells Fargo maintains ASND with a strong buy rating and raises their ASND price target from $289.00 to $295.00, on Aug 8, 2025.
Wells Fargo's Derek Archila raised their price target on Ascendis Pharma A (NASDAQ: ASND) by 2.1% from $289 to $295 on 2025/08/08. The analyst maintained their Strong Buy rating on the stock.
Ascendis Pharma A reported its Q2 2025 earnings.
In light of the solid results, Archila predicted a 5% to 10% increase in the price of the stock.
According to the analyst, the removal of the MBX overhang should further boost the stock price in the short term as U.S. Yorvipath launch revenues continue to grow considerably.
Archila told readers "it is not too late to own this launch."
For Q2 2025, Ascendis Pharma A reported:
Management did not provide EPS and revenue guidance in its press release.
President & CEO Jan Mikkelsen commented: “With the robust global uptake of YORVIPATH and with TransCon CNP under U.S. FDA priority review, Ascendis is on the verge of bringing our third high-value medicine to patients and substantially transforming our financial profile.
“We expect our engine for future innovation to drive continued momentum as we aim to address unmet medical needs in endocrine rare diseases and other large indications for years to come on our path to fulfilling Vision 2030.”
Alex Thompson, a top 20% analyst from Stifel Nicolaus maintains ASND with a strong buy rating and raises their ASND price target from $212.00 to $254.00, on Aug 8, 2025.
Maxwell Skor, a bottom 17% analyst from Morgan Stanley assumes ASND with a strong buy rating and announces their ASND price target of $250.00, on Jul 3, 2025.
Leland Gershell, a top 4% analyst from Oppenheimer maintains ASND with a buy rating and raises their ASND price target from $215.00 to $224.00, on Jun 13, 2025.
You can dig deeper into what analysts are forecasting on the Ascendis Pharma A stock forecast page.
Last year, ASND revenue was $418.98M. Over the past five year, ASND's revenue has increased by 104.09% per year. This was faster than the Biotechnology industry average of 65.21%.
Find out more about ASND's earnings and revenue performance here.
In the last 12 months, insiders at ASND have not bought or sold any shares.
Get more info about who owns ASND shares here.
No, Ascendis Pharma A doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
There are two main options:
Press the Open button and your broker will execute the order.
If you want more info about investing in stocks on eToro, click the helpful video below:
Now that you own some shares in ASND, you'll want to stay up-to-date on your stock purchase.
Put ASND on a watchlist to see the latest developments about your ASND stock.
To summarize, here are the 6 steps for buying Ascendis Pharma A stock:
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you would like to keep tabs on your investment in Ascendis Pharma A, create a watchlist on WallStreetZen today.